Navigation Links
Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit
Date:5/25/2010

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics.

Minneapolis, MN (PRWEB) May 25, 2010 -- The Agenda for Arrowhead’s 4th Annual Pain Therapeutics Summit, set to take place on October 4th-5th, 2010 in Philadelphia, has been announced.

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics.

Topics covered at this year’s Summit include:

Regulatory hurdles in pain drug development
Animal models for pain drug discovery research
Clinical development models
Trial Designs
Abuse-deterrent opioids
Long-term opioid use
Next generation therapeutics for pain
Trends in pain drug development
Preclinical and clinical activity in pain space
FDA Update
Market direction of the field of pain therapeutics
Translational pain research
Competitive landscape
Mixing basic science, drug development and clinical practice
Discovery targets: TRPV, TRPA, TRPM8, NGF antagonists, Nav1.7, P2X4, P2X7
Abuse liability and safety (REMS)
Novel mechanisms of action for future pain therapies

Speakers at this year’s event include:

Jeffrey S. Mogil, Ph.D., E.P. Taylor Chair in Pain Studies, Canada Research Chair in Genetics of Pain, McGill University

William K. Schmidt, Ph.D., Vice President, CG Pharmaceuticals

Theodore Cicero, Ph.D., Professor of Psychiatry, Anatomy & Neurobiology, Washington University in St. Louis
David Hewitt, MD, Senior Director, Clinical Neuroscience, Merck & Co.

Gary W. Jay, MD, DAAPM, FAAPM, Senior Director, Clinical Disease Area Expert - Pain, Pfizer, Inc.

Lynn R. Webster, MD, FACPM, FASAM, Medical Director and Founder, Lifetree Clinical Research & Pain Clinic, Director-At-Large, American Academy of Pain Medicine

Dr. Luca Benatti, CEO, Newron

Andy Billinton, Ph.D., Behavioral and Translational Pharmacology Leader, Pain, Neurosciences, GlaxoSmithKline

Jennifer Bolen, JD, Founder, The Legal Side of Pain (A division of the J. Bolen Group, LLC)

Michael Gold, Ph.D., Associate Professor, Anesthesiology, University of Pittsburgh

James R. Gorman, MD, Ph.D., CEO and Chief Medical Officer, BioAssets Development Corporation

Hyungsuk Kim, DDS, Ph.D, Staff Scientist, NINR, National Institutes of Health

Jennifer Laird, Ph.D., Senior Principal Scientist, AstraZeneca R&D

Frédérique Menzaghi, Ph.D., Vice President Research & Development, Cara Therapeutics

Patricia Richards, MD, Ph.D., Chief Medical Officer, QRx Pharma

For the complete list of speakers as well as the agenda, please visit www.paintherapeuticsummit.com or call 1-312-244-3703.

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4041724.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. FASEB Encourages NIGMS to Broaden Scientific Training Opportunities
2. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
3. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
4. Scientific breakthrough in genetic studies of animal domestication
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents
7. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
8. Boston Scientific Announces Completion of $2 Billion Senior Notes Offering
9. Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum
10. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
11. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased to announce ... determined to be appropriate as a screening test at dairies and farms for raw ... system, and the Charm EZ Lite system. These systems are a combination incubator and ...
(Date:6/20/2017)... ... 20, 2017 , ... HorizonScan is providing food and ingredient ... likely threat to their products at the annual IFT conference in Las Vegas, ... expo attracts over 20,000 attendees representing food science professionals from over 90 countries ...
(Date:6/20/2017)... ... 20, 2017 , ... Do More with OHAUS , With the launch of ... in the weighing industry, to extending its expertise across the entire laboratory to a ... and more, allowing for its customers to 'Do More' in the lab. ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., ... today that it is launching two new additions of its award-winning cloud-based platform ... capabilities at the DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):